Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage presently has a $0.75 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 7.14% from the stock’s previous […]
Equities research analysts expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) to report sales of $4.56 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings. The lowest sales estimate is $3.10 million and the highest is $5.85 million. Syros Pharmaceuticals posted sales of $4.83 […]
Analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) will report earnings of ($0.48) per share for the current quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.45). Syros Pharmaceuticals reported earnings per […]
Analysts forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) will report ($0.48) earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for Syros Pharmaceuticals’ earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.51). Syros Pharmaceuticals posted earnings per share of ($0.23) in the same quarter […]
Wall Street brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) to announce sales of $4.56 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings. The lowest sales estimate is $3.10 million and the highest is $5.85 million. Syros Pharmaceuticals reported sales of $4.83 million in the […]